We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

54 hedge funds and large institutions have $9.62M invested in Clearside Biomedical in 2023 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 13 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 5

16% more call options, than puts

Call options by funds: $136K | Put options by funds: $117K

8% more funds holding

Funds holding: 50 → 54 (+4)

6% more capital invested

Capital invested by funds: $9.09M → $9.62M (+$532K)

0.02% less ownership

Funds ownership: 0.95% → 0.93% (-0.02%)

23% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 13

Holders
54
Holders Change
+4
Holders Change %
+8%
% of All Funds
0.85%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
10
Reduced
13
Closed
5
Calls
$136K
Puts
$117K
Net Calls
+$19K
Net Calls Change
-$32K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$139K
2
TC
TownSquare Capital
Utah
+$126K
3
Stifel Financial
Stifel Financial
Missouri
+$54.9K
4
VF
Virtu Financial
New York
+$38.8K
5
Millennium Management
Millennium Management
New York
+$38.2K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$141K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$118K
3
Janney Montgomery Scott
Janney Montgomery Scott
Pennsylvania
-$104K
4
LNC
Lincoln National Corp
Pennsylvania
-$96K
5
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
-$91.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
1
Carmignac Gestion
France
$2.69M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$2.43M – – –
BlackRock
3
BlackRock
New York
$911K +$17K +986 +2%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$559K -$35.5K -2,060 -6%
Renaissance Technologies
5
Renaissance Technologies
New York
$377K -$141K -8,180 -27%
BCM
6
Bridgeway Capital Management
Texas
$313K -$13.8K -800 -4%
State Street
7
State Street
Massachusetts
$217K – – –
First Manhattan
8
First Manhattan
New York
$196K – – –
Morgan Stanley
9
Morgan Stanley
New York
$194K +$139K +8,077 +235%
JJ
10
Johnson & Johnson
New Jersey
$190K – – –
BWM
11
Brown Wealth Management
Illinois
$123K +$126K +7,333 New
TC
12
TownSquare Capital
Utah
$123K +$126K +7,333 New
Two Sigma Advisers
13
Two Sigma Advisers
New York
$112K -$18.5K -1,074 -14%
Northern Trust
14
Northern Trust
Illinois
$107K -$465 -27 -0.4%
NFC
15
Northeast Financial Consultants
Connecticut
$93K – – –
WIC
16
Water Island Capital
New York
$81.2K +$8.61K +500 +12%
Assenagon Asset Management
17
Assenagon Asset Management
Luxembourg
$80.4K -$91.7K -5,324 -53%
Stifel Financial
18
Stifel Financial
Missouri
$67.8K +$54.9K +3,187 +375%
SF
19
Synovus Financial
Georgia
$65K – – –
S
20
SignatureFD
Georgia
$60.7K – – –
BCV
21
Banque Cantonale Vaudoise
Switzerland
$45K – – –
SWP
22
Stratos Wealth Partners
Ohio
$44.2K +$16.4K +950 +57%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$41.8K +$1.33K +77 +3%
VF
24
Virtu Financial
New York
$38K +$38.8K +2,256 New
Millennium Management
25
Millennium Management
New York
$37.3K +$38.2K +2,220 New
1
2 3

CLSD Hedge Fund Activity: Q2 2023 in Review

54 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q2 2023, worth a combined $9.62M — up 5.9% from $9.09M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CLSD positions and 5 closed out — a net gain of 5 holders — while 10 added to existing stakes and 13 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $139K. The largest seller was Renaissance Technologies, cutting an estimated $141K.

  • 54 institutional investors held Clearside Biomedical (CLSD) as of Q2 2023, up from 50 in Q1 2023.
  • Funds reported $9.62M of Clearside Biomedical stock for Q2 2023, up 5.9% quarter-over-quarter.
  • 10 funds opened new Clearside Biomedical positions in Q2 2023 and 5 closed out, a net change of +5 holders.
  • The largest Clearside Biomedical buyer in Q2 2023 was Morgan Stanley, an estimated $139K added.
  • The largest Clearside Biomedical seller in Q2 2023 was Renaissance Technologies, an estimated $141K sold.

Based on aggregated 13F filings for Q2 2023.